Accessibility Menu

Cerenome(NASDAQ) CNSY

Market Cap$26.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-100%
1 Year-78%
1 Month-4%
$3.79
-1.30%
-0.05Today
After hours$3.77-$0.02 (-0.53%)
Cerenome last closing stock price
MetricPriceDate
Last closeUSD 3.832026-08-11
Cerenome stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.28%USD 3.962026-08-04
1 month-4.25%USD 4.002026-07-10
3 month-32.81%USD 5.702026-05-13
Year to date-70.1%USD 12.812025-12-31
1 year-78.11%USD 17.502025-08-11
3 year-93.87%USD 62.502023-08-11
5 year-99.5%USD 761.252021-08-12
Since inception-100%USD 10,404,949.382003-07-01

Cerenome Financials at a Glance

Market Cap

$26.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.18

Net Income (TTM)

-$15.89

EPS (TTM)

-$3.27

P/E Ratio

-1.17

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$3.79

Volume

4,250

Open

$3.79

Previous Close

$3.83

Daily Range

$3.65 - $3.85

52-Week Range

$2.90 - $23.43

Estimated Earnings Date

Aug 19, 2026

CNSY News

Foolcom-Featured.png

Plus Therapeutics Posts Q2 Profit Jump

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cerenome

Plus Therapeutics, Inc. is a U.S.-based pharmaceutical company dedicated to developing targeted radiotherapeutics for central nervous system cancers. With innovative technologies, they focus on delivering radiation directly to tumors, aiming to reduce damage to healthy tissues. This approach could revolutionize treatment for rare and challenging cancer types.

Products and Services

Rhenium-186 obisbemeda: A radiotherapeutic designed for CNS cancers delivered directly to tumor sites.

Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere: Targeted treatment for solid organ cancers like liver cancer.

Research and development in radiotherapeutic technologies.

What Makes Plus Therapeutics, Inc. Special

Plus Therapeutics leverages its proprietary nanoliposome technology to deliver radiotherapeutic agents precisely, potentially improving efficacy and minimizing damage to healthy tissues. This sets them apart by addressing unmet needs in rare and difficult-to-treat cancer markets.

Five Things You Need to Know

Focus on treating rare cancers with significant unmet medical needs.

Leading product, Rhenium-186 obisbemeda, is in advanced clinical trials for various CNS cancers.

Strong strategic partnerships enhance supply chain and development capabilities.

Headquartered in Texas, near major cancer research institutions.

Uses a patented platform technology with potential applications beyond current cancer targets.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Marc H. Hedrick, MD, MBA

Website

www.plustherapeutics.com

Headquarters

Houston, TX, US

CNSY Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-85.47%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$26.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.88M

Volume

4.25K

Avg. Volume

156.40K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Cerenome Performance Analysis

Cerenome annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 224,000N/A
20232023-12-31USD 4,913,0002093.3%
20242024-12-31USD 5,824,00018.5%
20252025-12-31USD 5,213,000-10.5%
Cerenome annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -289.59-30.3%
20232023-12-31USD -105.99-63.4%
20242024-12-31USD -58.52-44.8%
20252025-12-31USD -7.19-87.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.03

+1.0%

Gross Profit

$0.92

+1.0%

Gross Margin

89.40%

+1.1%

Market Cap

$26.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$0.81

N/A

Employees

28

N/A

Net Income

-$6.95

+0.4%

EBITDA

-$7.01

+2.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.75

-62.2%

Total Debt

$0.73

+18.1%

Accounts Receivable

$1.35

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.73

+18.1%

Return on Assets

-99.41%

+0.3%

Return on Invested Capital

72.62%

+0.5%

Free Cash Flow

-$7.06

+1.1%

Operating Cash Flow

-$6.24

+1.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,720.28-0.00%
^DJIDJI
$53,833.46-0.00%
^IXICNASDAQ
$26,389.23-0.01%
BTCBitcoin
$63,536.00-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.44+0.03%
SMCISuper Micro Computer
$31.60+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.06-0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.14+0.01%

Questions About CNSY

What is the current price of Cerenome?

Cerenome is trading at $3.83 per share.

What is the 52-week range for Cerenome?

Over the past 52 weeks, Cerenome has traded between $2.90 and $23.43.

How much debt does Cerenome have?

As of the most recent reporting period, Cerenome reported total debt of $725.00K.

How much cash does Cerenome have on hand?

Cerenome reported $3.02M in cash and cash equivalents in its most recent financial results.

What is Cerenome’s dividend yield?

Cerenome does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services